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Bipolar disorder is a major mental illness affecting 1% of the world's population and whilst
numerous treatments are available, lithium retains a key position in major treatment guidelines.
Despite its widespread clinical use, the mechanism of action of lithium is unknown. This
thesis uses magnetic resonance imaging techniques in order to expand our understanding
of where and how lithium acts within the brain with regards to structural abnormalities that
occur in bipolar disorder.
The development of a novel imaging technique,7Li-MRI, has enabled researchers to non-
invasively measure lithium distribution in the brain. However, the stability of lithium
distribution over time is unknown. We investigated the scan-rescan comparability of this
technique and showed that whilst7Li-MRI images exhibit high variability in terms of signal
magnitude, the pattern of brain lithium distribution remains constant over one week.
To investigate previous ndings which suggest an association between lithium use and
increased white matter integrity we applied7Li-MRI alongside diffusion MRI to explore
the spatial association between lithium distribution and white matter integrity in patients
receiving treatment with lithium. Our ndings revealed a positive association between local
lithium signal and white matter integrity, adding support to ndings which suggest that
lithium exhibits a neuroprotective effect in white matter.
Using a quantitative imaging technique we identied elevated longitudinal relaxation in the
brains of patients with bipolar disorder relative to controls. The biological underpinnings
and potential for this technique to serve as a diagnostic biomarker are discussed.
In summary, using a range of magnetic resonance imaging acquisition techniques we have
identied a number of structural brain differences between healthy subjects, lithium-treated
patients and lithium-naïve patients.
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Bipolar disorder is a mental illness with an unknown aetiology. It has a prevalence of
approximately 1% in the population and is a leading cause of disability worldwide (Krahn,
2011). Owing to the early onset (median age of 25 years), severity, and chronic nature of
bipolar disorder, it is reported to be responsible for the loss of more disability-adjusted life
years than diseases such as Alzheimer's disease, epilepsy and all forms of cancer (Merikangas
et al., 2011).
Bipolar disorder is characterised by the experience of depressive and manic episodes, and
sufferers are more likely to commit suicide. Treatment with lithium is an effective way of
managing episodes and preventing relapse in patients with bipolar disorder, additionally
reducing suicidal behaviour. However, it is not known how lithium works, nor why it is
an effective treatment in some individuals but not others. A greater understanding of how
lithium exerts its therapeutic effects might provide insights into the pathophysiology of
bipolar disorder, or separate out a subgroup of lithium responders with different illness
characteristics and underlying pathology.
2 Introduction
1.1.1 Diagnosis
Diagnosis of bipolar disorder is distinguished from other affective disorders such as major
depressive disorder by patients experiencing manic and/or hypomanic episodes. The term
bipolar disorder is used to describe a range of related disorders consisting of multiple sub-
types. The two main sub-types of bipolar disorder listed in the Diagnostic and Statistic
Manual Version 5 (DSM-5) are Bipolar Disorder Type I and Bipolar Disorder Type II
(American Psychiatric Association, 2013):
• Bipolar Disorder Type I is characterised by the experience ofmania. The manic
episode may have been preceded by and may be followed by hypomanic or major
depressive episodes. The lifetime prevalence of BD Type I is estimated to be 0.6%.
• Bipolar Disorder Type II is characterised by the experience of hypomaniaanddepres-
sion; the experience of a manic episode would rule out Type II diagnosis and elevate
the diagnosis to Type I. The lifetime prevalence of BD Type II is estimated to be 0.4%.
Individuals with bipolar disorder are at an increased risk of suicide and experience cognitive
impairment; although this is not currently part of the diagnostic criteria. The DSM-5 criteria
for manic, hypomanic and depressive episodes are given in Boxes 1-3 on pages 3, 4 and
5, respectively. Whilst the DSM-5 species other subtypes of bipolar disorder such as
cyclothymic disorder, medication-induced bipolar disorder and “other specied and related
disorder”, the data presented and discussed in this thesis is primarily concerned with Type I
and Type II manifestations of bipolar disorder.
Bipolar disorder is a highly recurrent disorder. It has been reported that the average duration
of episodes last between two to seven months (Angst and Sellaro, 2000), though this can
vary signicantly between individuals, and recurrences tend to become closer together as
the disorder progresses (Haldipur, 1999). Successful response to treatment is therefore
reected by an increase in the duration of time between episodes. Whilst bipolar disorder
was considered historically as a “functional psychosis” primarily caused by neurochemical
derangement, it is now becoming clear that there are underlying structural changes and
perhaps even progressive changes in brain structure and function that occur during the course
of bipolar disorder (Schneider et al., 2012).
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Box 1. Criteria for a manic episode.
(A) Distinct period of abnormally and persistently elevated, expansive, or irritable mood and
abnormally and persistently increased activity or energy, lasting at least 1 week and present
most of the day, nearly every day (or any duration if hospitalisation is necessary).
(B) During the period of mood disturbance and increased energy and activity, three (or more)
of the following symptoms (four if the mood is only irritable) are present to a signicant
degree and represent a noticeable change from usual behaviour:
• Inated self-esteem or grandiosity
• Decreased need for sleep (e.g. feels rested after only 3 hours of sleep)
• More talkative than usual or pressure to keep talking
• Flight of ideas or subjective experience that thoughts are racing
• Distractibility (i.e, attention too easily drawn to unimportant or irrelevant external
stimuli), as reported or observed
• Increase in goal-directed activity (either socially, at work or school, or sexually) or
psychomotor agitation
• Excessive involvement in activities that have a high potential for painful consequences
(e.g. engaging in unrestrained buying sprees, sexual indiscretions, or foolish business
investments)
(C) The mood disturbance is sufciently severe to cause marked impairment in social or
occupational functioning or to necessitate hospitalisation to prevent harm to self or others, or
there are psychotic features.
(D) The episode is not attributable to the physiological effects of a substance (eg, a drug of
abuse, a medication, other treatment) or to another medical condition.
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Box 2. Criteria for a hypomanic episode.
(A) A distinct period of abnormally and persistently elevated, expansive, or irritable mood
and abnormally and persistently increased activity or energy, lasting at least 4 consecutive
days and present most of the day, nearly every day.
(B) During the period of mood disturbance and increased energy and activity, three (or more)
of the following symptoms (four if the mood is only irritable) have persisted, represent a
noticeable change from usual behaviour, and have been present to a signicant degree:
• Inated self-esteem or grandiosity
• Decreased need for sleep (e.g. feels rested after only 3 hours of sleep)
• More talkative than usual or pressure to keep talking
• Flight of ideas or subjective experience that thoughts are racing
• Distractibility (i.e. attention too easily drawn to unimportant or irrelevant external
stimuli), as reported or observed
• Increase in goal-directed activity (either socially, at work or school, or sexually) or
psychomotor agitation
• Excessive involvement in activities that have a high potential for painful consequences
(e.g. engaging in unrestrained buying sprees, sexual indiscretions, or foolish business
investments)
(C) The episode is associated with an unequivocal change in functioning that is uncharacter-
istic of the individual when not symptomatic.
(D) The disturbance in mood and the change in functioning are observable by others.
(E) The episode is not severe enough to cause marked impairment in social or occupational
functioning or to necessitate hospitalisation. If there are psychotic features, the episode is, by
denition, manic.
(F) The episode is not attributable to the physiological effects of a substance (e.g. a drug of
abuse, a medication, other treatment).
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Box 3. Criteria for a major depressive episode.
(A) Five (or more) of the following symptoms have been present during the same 2-week
period and represent a change from previous functioning; at least one of the symptoms is
either (1) depressed mood or (2) loss of interest or pleasure:
• Depressed mood most of the day, nearly every day, as indicated by either subjective
report (e.g., feels sad, empty, or hopeless) or observation made by others (e.g. appears
tearful). (Note: In children and adolescents, can be irritable mood.)
• Markedly diminished interest or pleasure in all, or almost all, activities most of the day,
nearly every day (as indicated by either subjective account or observation).
• Signicant weight loss when not dieting or weight gain (e.g. a change of more than
5% of body weight in a month), or decrease or increase in appetite nearly every day.
(Note: In children, consider failure to make expected weight gain.)
• Insomnia or hypersomnia nearly every day.
• Psychomotor agitation or retardation nearly every day (observable by others; not
merely subjective feelings of restlessness or being slowed down).
• Fatigue or loss of energy nearly every
• Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional)
nearly every day (not merely self-reproach or guilt about being sick).
• Diminished ability to think or concentrate, or indecisiveness, nearly every day (either
by subjective account or as observed by others).
• Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without
a specic plan, or a suicide attempt or a specic plan for committing suicide.
(B) The symptoms cause clinically signicant distress or impairment in social, occupational,
or other important areas of functioning.
(C) The episode is not attributable to the physiological effects of a substance or another
medical condition.
6 Introduction
The aetiology of bipolar disorder remains incompletely denes and clinical heterogeneity
presents a challenge with regards to understanding this. There may be a common cause
with differing manifestations or several pathologically distinct conditions with overlapping
presentations. Whilst it is difcult to disentangle cause from consequence when it comes
to biological differences between patients and healthy individuals, it is evident that patients
with bipolar disorder exhibit a number of structural brain abnormalities.
1.1.2 Structural abnormalities in Bipolar Disorder
A considerable amount of research has been undertaken in order to try and identify structural
and functional changes in the brains of patients with bipolar disorder. In doing so it is
hoped that such differences will provide insights into the pathophysiology of bipolar disorder,
enable earlier diagnosis, targeted intervention, and provide a basis for the development of
new treatments. One of the main tools of assessing structural and functional brain changesin
vivo is via Magnetic Resonance Imaging (MRI). The following section aims to introduce
what neuroimaging techniques have revealed about some of the most commonly identied
structural changes that occur in the brain during bipolar disorder. More detailed information
regarding the neuroimaging methods themselves can be found in Chapter 2.
Ventricles
Ventriculomegaly, a term used to describe enlargement of the ventricles, is a feature which
has been repeatedly found to be present in patients with bipolar disorder. Results from
a meta-analysis of studies which have used MRI to assess brain morphometry in bipolar
disorder suggest that patients consistently exhibit an increased ventricle to brain ratio in
the right lateral ventricle, with other ventricles exhibiting greater heterogeneity in terms of
enlargement (McDonald et al., 2004). Moreover, there is also evidence to suggest that the
lateral ventricles are larger in patients who have experienced multiple episodes relative to rst-
episode patients (Strakowski et al., 2002) and in patients with BD Type I vs Type II (Hibar
et al., 2016). However, whilst ventricular enlargement is a feature which is relatively easy to
detect using structural MRI, it is not a feature specic to bipolar disorder. Ventriculomegaly
is common to a range of neurological disorders and is perhaps most apparent and more
commonly associated with dementia (Forstl et al., 1995). As a result, this makes it difcult
to attribute a specic link between ventriculomegaly and bipolar disorder.
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Grey matter
There is substantial evidence from a large number of independent studies to suggest that
patients with bipolar disorder exhibit a widespread reduction in grey matter volume (Abé
et al., 2016; Bora et al., 2010; Foland-Ross et al., 2011; Hibar et al., 2017, 2016). In
a meta analysis published by the ENIGMA consortium which included the analysis of
1837 MRI images from patients with bipolar disorder and 2582 unrelated adult healthy
controls, it was concluded that in terms of changes in cortical thickness, patients exhibit the
greatest magnitude of cortical thinning in the left pars opercularis, left fusiform gyrus and
left rostral middle frontal cortex (Hibar et al., 2017). In terms of subcortical grey matter
volume, the same group report signcant reductions in volume bilaterally in the amygdala,
hippocampus and thalamus (Hibar et al., 2016). However, as with vectricular enlargement,
widespread reductions in grey matter volume is another feature that is common to a number
of neurological conditions and therefore non-specic to bipolar disorder. Moreover, it is
possible that these two ndings are inter-related, as loss of subcortical volume surrounding
the ventricles will present itself as ventricular enlargement. Attempts to classify patients from
controls based upon such morphometric data have thus far been unsuccessful, yielding low
classication accuracy (65%), thereby highlighting the lack of specicity of this structural
feature with regards to bipolar disorder (Nunes et al., 2018).
White matter
Whilst changes in grey matter volume have received considerable attention throughout
the bipolar disorder literature, until relatively recently less work had been performed to
investigate changes in white matter structure. Perhaps the rst recognition of white matter
abnormalities in bipolar disorder can be attributed to the identication of an increased
frequency of white matter hyperintensities (WMH), which appear as bright spots within
white matter (Figiel et al., 1991). An increased frequency of WMH in bipolar disorder is a
feature which has been replicated numerous times throughout the literature, with this effect
being seen across all age ranges (Aylward et al., 1994; Dupont et al., 1995; Lloyd et al., 2009;
Regenold, 2008; Videbech, 1997). However, WMHs are also found to be more common in
older individuals during healthy ageing and a link between WMHs and the pathophysiology
of BD has yet to be established.
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The development of a technique known as diffusion MRI (for further details see section
2.4) enables the examination of the microstructural properties of tissue by mapping water
molecule diffusion. In pure uid states, water diffuses equally in all directions (isotropic),
whilst in neurons water cannot readily cross the hydrophobic myelin sheaths and diffusion is
restricted (anisotropic) along the direction of the axon. The parallel conguration of axons
in white matter renders this directional diffusion detectable at the microstructural scale,
reected in the dMRI-derived parameter of fractional anisotropy (FA). Reductions in FA
have been shown to correspond with demyelination and axonal injury (Boretius et al., 2012;
Song et al., 2002). Patients with bipolar disorder have been shown to exhibit decreased FA
within white matter (Adler et al., 2006; Benedetti et al., 2011; Bruno et al., 2008; Favre et al.,
2019) and a meta analysis of whole brain voxel-wide FA studies has identied two signicant
clusters near the right parahippocampal gyrus and right subgenual cingulate cortex which
exhibit consistently reduced FA during bipolar disorder (Vederine et al., 2011). In addition to
regional white matter damage, alterations in whole brain connectivity have been identied
during bipolar disorder (Collin et al., 2016). This study found a reduction in the connectivity
strength of inter-hemispheric connections in patients diagnosed with bipolar disorder type I
relative to healthy controls.
T1 relaxation
Longitudinal relaxation (T1) is a biophysical property of protons which is sensitive to
tissue properties including myelin, macromolecular content, iron and water. “Quantitative
relaxometry” describes a eld of study in which imaging techniques may be used to quantify
this T1 property (for further details regarding this technique see section 2.3). There is some
evidence from studies employing relaxometry to suggest that patients with bipolar disorder
exhibit differences in proton relaxation times within the brain. For example, longitudinal
relaxation (T1) within the frontal and temporal lobes has been shown to be higher in patients
with bipolar disorder (Rangel-Guerra et al., 1983). Elevated T1 is associated with lower
myelin content, supporting the nding that reductions in white matter integrity occur during
bipolar disorder. Whilst this report of elevated T1 in bipolar disorder is an old observation, the
development of high resolution quantitative mapping techniques are beginning to attract more
attention, leading to the identication of novel ndings and development of new hypotheses.
For example, recent studies employing a quantitative T1r mapping technique (a parameter
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sensitive to T1) have found that T1r is higher in cerebral and cerebellar white matter in
patients with bipolar disorder compared to controls (Johnson et al., 2018, 2015).
Summary
A large number of structural brain changes have been identied in bipolar disorder, however,
changes which are specic to bipolar disorder have yet to be found. As a result, it is currently
not possible to diagnose and treat patients based solely upon observable structural brain
changes. Despite this, structural changes have already provided a number of insights into the
potential pathophysiology of bipolar disorder. Moreover, by characterising such differences,
researchers can begin to investigate whether novel or existing therapies are able to prevent or
reverse such changes. In doing so, this may reveal more about the mechanism of action of
such treatments, whilst also holding the potential to further understand why certain treatments
work in certain subsets of patients.
1.2 Lithium therapy in Bipolar Disorder
Whilst there are now a range of treatments available during the management of bipolar
disorder, lithium, which is cited as the rst drug to be used in all of modern psychiatry,
remains the rst line treatment for bipolar disorder (Shorter, 2009). Lithium has been
shown to be effective at treating both manic (Poolsup and de Oliveira, 2000) and depressive
episodes (Nolen and Bloemkolk, 2000), and effectively reduces the risk of suicide (Cipriani
et al., 2005). The following section introduces the discovery and clinical use of lithium
during bipolar disorder, and provides an overview of research into lithium's mechanism of
action.
1.2.1 Discovery and use of lithium
Discovery of lithium
The rst medicinal use of lithium was recognised as far back as the mid 19th century. During
this time Alexander Ure recognised the ability of lithium to bind to uric acid and in turn
advocated the use of lithium as a treatment for bladder stones caused by the crystallisation
of uric acid. At around the same time the English physician Alfred Garrod noted high
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levels of uric acid in his patients with gout (Garrod, 1860) and subsequently popularised the
treatment of gout and “brain gout” using lithium, thereby marking itself as an early reference
to potential use of lithium for psychiatric purpose.
Throughout the latter half of the 19th century a number of references to the use of lithium
for psychiatric purposes may be found. For example, references were made to the use of
lithium bromide as an anticonvulsant (Mitchell, 1870), and later on for its efcacy in treating
“general nervousness” (Mitchell, 1877). However, it wasn't until the end of the 19th century
before the use of lithium became recognised for its efcacy at treating depressive symptoms;
this came when the Danish psychiatrist Frederik Lange reported on the use of lithium during
the treatment of “melancholic depression” (Schioldann, 2001).
The recognition of the use of lithium during the treatment of mania did not come about
until the middle of the 20th century. This occurred when the Australian psychiatrist John
Cade (Cade, 1949) hypothesised that some of his patients' “psychotic excitement” could
be attributed to abnormally high uric acid levels. Cade noted that following the treatment
of his patients with combinations of lithium citrate and lithium carbonate, a subset of
patients responded extremely well to treatment, exhibiting a dramatic reduction in their
manic symptoms.
Despite the discovery made by Cade in 1949, lithium was not ofcially approved by the
American Food and Drug Administration until 1970. This failure to approve lithium is
thought to be in part due to a concurrent report on lithium's toxicity during its use as a
table salt substitute for patients with congestive heart failure (Corcoran and Page, 1949). In
the period leading up to 1970 lithium was prescribed without FDA approval by a number
of American physicians (Shorter, 2009); however, the fact that lithium was not ofcially
approved by the FDA meant that the efcacy and safety of lithium could not be established by
scientists working in the US. Despite its ban in the US, experiments with lithium continued
to be trialled by a small number of psychiatrists in Europe (Schou and Mogens, 1958).
The efcacy of lithium treatment as a means of treating acute mania was easy to replicate,
however, proof of it's efcacy during relapse prevention took much longer to become widely
accepted. Owing to the continuous replication of positive ndings regarding the benets of
lithium use during the treatment of mania and relapse prevention, lithium therapy remains
the gold standard treatment for bipolar disorder today.
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Clinical use
Lithium is administered orally as it is easily absorbed by the gut. During lithium therapy
serum lithium concentration is aimed to be kept between the therapeutic range of 0.6 -
0.8 mmol/L (or 0.8 - 1.0 mmol/L in severe cases or non-responders) and patients must be
closely monitored in order to avoid lithium toxicity (Goodwin et al., 2016). Serum lithium
concentration can be measured with condence and ease by testing blood samples (Alda and
Martin, 1988). However, although the monitoring of serum levels is used to minimise the risk
of toxicity, it does not guarantee therapeutic response. Moreover, in certain cases patients can
exhibit signs of lithium toxicity when serum concentrations are within the target therapeutic
range. Whilst the mechanism of toxicity occuring within the therapeutic range is unknown,
techniques which enable quantication of brain lithium levelsin vivo such as7Li-MRS (see
section 1.3.2) have been used to attempt to determine the relationship between serum and
brain lithium concentration with the aim of trying to understand whether this relationship is
related to toxicity and therapeutic response.
1.2.2 Mechanism of action
Despite its widespread use, lithium's exact mechanism of action remains elusive. The
actions of lithium at a cellular level are manyfold and several effects have been well char-
acterised. The following section provides an overview of some of the biological actions of
lithium alongside evidence relating to their potential efcacy during the treatment of bipolar
disorder.
Effect on neurotransmission
The effects of lithium on neurotransmitter systems have been investigated and characterised
in both preclinical and clinical studies. The focus of this work has been on monoaminergic
systems, owing to their importance in mood regulation. Lithium augments serotonergic
neurotransmission (Blier and De Montigny, 1985) and this effect may be important in its
antidepressant action and possibly in its ability to reduce suicidal behaviours. As lithium
attenuates some of the psychoactive effects of amphetamines (Vankammen and Murphy,
1975), its effects on dopaminergic neurotransmission have received considerable attention.
Evidence from microdialysis studies suggest that the anti-manic effects of lithium may be
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due to a reduction in presynaptic dopamine release (Ferrie et al., 2005, 2006). The effects of
lithium administration on noradrenergic neurotransmission appear more mixed, with some
evidence to suggest that the effect of lithium on noradrenaline excretion may depend upon
mood state (Beckmann et al., 1975; Bowers and Heninger, 1977; Greenspan et al., 1970).
Together, such ndings have led to the suggestion that lithium may work via the modulation
of monoaminergic pathways (Baptista et al., 1993; Ferrie et al., 2008). However, the complex
way in which lithium affects such systems, combined with the technical difculty associated
with quantifying neurotransmissioni vivo, means that a comprehensive understanding of
the way in which lithium modulates neurotransmission on a whole systems level is still
lacking.
Effect on secondary messengers
Lithium has been shown able to modulate the concentration of cellular signalling molecules
which are important for maintaining neuronal integrity and promoting synaptic plasticity.
The detection of molecular compounds can be achievedin vivousing a technique known as
Magnetic Resonance Spectroscopy (see section 1.3.2 for details) and this technique has been
used to study how the concentration of a range of compounds differ during bipolar disorder.
For example, lithium administration has been linked with an increased concentration of the
compound N-acetylaspartate (NAA) (Moore et al., 2000a), a cellular marker of neuronal
integrity. During this study associations between lithium use and increased NAA were
identied in regions which exhibited greatest grey matter density. The relationship between
lithium use and the concentration of the compound myo-inositol has gained particular interest
throughout the lithium literature. An apparent ability of lithium to reduce the cellular content
of myo-inositol has led this effect to become known as the “inositol depletion hypothesis”
(Allison and Stewart, 1971). During preclinical experiments, lithium administration has been
shown to increase the spread of axonal growth cones (Williams et al., 2002), an effect which
was reversed following the addition of myo-inositol (Harwood, 2005; Shaltiel et al., 2007),
suggesting that the relationship between lithium and myo-inositol may play a role during
the facilitation of synaptic plasticity. However, debate still remains as to whether lithium
does in fact augment myo-inositol (Moore et al., 1999), or rather decreases it (Forester et al.,
2008); it is possible that acute administration of lithium decreases myo-inositol levels with
the reverse effect occurring following chronic administration.
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Neuroprotection
Lithium has repeatedly been reported to exhibit neuroprotective (Forlenza et al., 2014),
neurotrophic (Quiroz et al., 2010) and neuroplastic (Gray and McEwen, 2013) properties.
For example, during preclinical studies it has been shown that lithium inhibits the apop-
totic enzyme Glycogen Synthase Kinase 3b (GSK-3b). Whilst the precise mechanism of
inhibition is unknown, this may occur via competition with Mg2+ as a co-factor (Freland
and Beaulieu, 2012). GSK-3b is an enzyme expressed widely throughout body and brain
tissue and is involved in the phosphorylation of compounds leading to their inactivation or
degradation. Upregulation of GSK-3b activity is associated with neuronal apoptosis (Hetman
et al., 2000), and hence inhibition of this enzyme by lithium can protect against cell death.
As well as being able to inhibit the processes preceding apoptosis, lithium administration has
also been shown to actively promote cell proliferation. However, it is yet unclear whether
such proliferation translates into fully differentiated functional neurons downstream (Agam
et al., 2015; Zanni et al., 2017).
There is evidence from imaging studies to suggest that this ability of lithium to down-regulate
apoptosis and promote proliferation on a cellular level might lead to effects that are detectable
on a macro-scale. Multiple studies have shown using MRI that there is an association between
the use of lithium and an increased volume of grey matter (Bearden et al., 2008; Cousins et al.,
2013; Hibar et al., 2017; Lyoo et al., 2010; Monkul et al., 2007; Moore et al., 2000b; Yucel
and MacQueen, 2008; Zung et al., 2016). This widely replicated association between lithium
and increased grey matter volume has led to the suggestion that lithium may protect against
or even reverse grey matter changes that are known to occur during bipolar disorder (Hibar
et al., 2016). However, it has also been suggested that the association between increased
MRI measures of grey matter volume and lithium use may in fact be an imaging artefact
stemming from the ability of lithium to shorten proton longitudinal relaxation (T1). Lithium
administration in healthy individuals has been shown to reduce T1 times in grey matter
(Cousins et al., 2013), a phenomenon which is also known to occur in vitro when lithium
is added to aqueous solution (Fabricand and Goldberg, 1967). In a study showing elevated
T1r values in patients relative to controls, when patients were subdivided according to
medication use, it was found that patients using lithium exhibited lower T1r values than
patients using other medications; however, this nding was not replicated in a later study
(Johnson et al., 2018). In addition to a potential neuroprotective action in the cortex, there
is growing evidence to suggest an association between lithium use and protection of white
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matter structure. Patients with bipolar disorder undergoing lithium treatment have been
shown to exhibit higher white matter integrity relative to those treated with other medications
(Gildengers et al., 2015; Haarman et al., 2016; Macritchie et al., 2009; Sussmann et al., 2008),
and lithium has been shown to protect against reductions in white matter volume (Berk et al.,
2017). In Chapter 4 we investigate the association between lithium use and white matter
structure.
1.3 Lithium distribution
The prevailing inability to establish a clear link between the actions of lithium at a cellular
and systems level and its therapeutic properties suggests that lithium may not have a single,
targeted action during bipolar disorder. Instead an understanding of the actions of lithium
may be better framed in the same way as other common biologically active ions. After all,
the pharmacokinetic properties of lithium resembles other monovalent cations, and unlike
most pharmaceutical compounds lithium is not metabolised (Ward et al., 1994). Recognition
of lithium as an ion warrants the need for a concrete characterisation of lithium's distribution
throughout bodily tissues as it is clear that the distribution of ions is closely related to their
functions. For example, 99% of all calcium occurs in the skeleton (Bessey et al., 1935), 90%
of potassium is located intracellularly whereby it is important for maintaining resting state
potential (Palmer and Clegg, 2016), and 90% of sodium is located within extracellular uid
whereby it facilitates the generation of action potentials (Deane and Smith, 1952).
It is notable that while large quantities of such ions appear to concentrate in certain regions,
the remaining percentages also perform essential functions. For example, although 99%
of calcium occurs within bone, the remaining 1% is involved during a range of processes
including muscle contraction, respiration and long term potentiation (Clapham, 1995). Thus,
calcium exhibits non-uniform distribution and multi-functional properties. Lithium has
a disproportionately large hydration shell which restricts its ionic mobility in biological
systems, with some arguing that it has characteristics more closely comparable to calcium
and magnesium rather than sodium and potassium (Stern and Amis, 1959). Consistent with
this, lithium has been shown to accumulate in bone (Birch, 1976; Birch and Jenner, 1973),
whereby its accumulation is accompanied by a decrease in calcium concentration, and there
is evidence to suggest that a fraction of lithium incorporated into bone remains for at least
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nine months following discontinuation (Birch and Hullin, 1972). Based on the assumption
that lithium behaves similarly to other biologically active cations it may be hypothesised that
lithium is multi-functional, exhibits an uneven distribution throughout the body, and that the
distribution of lithium is related to it's function.
Although it is generally accepted that the actions of lithium which underpin its efcacy during
bipolar disorder occur within the brain, little work has been done to understand whether the
brain distribution of lithium is in some way spatially localised. Whilst some studies have
pointed towards localised effects of lithium; for example, it has been suggested that lithium
might act in the hippocampus to promote neurogenesis (O'Leary et al., 2012), others have
suggested that lithium exerts more widespread effects on white matter (Gildengers et al.,
2015). Regional specicity of lithium action could in theory be underpinned by uneven
distribution witheventissue sensitivity, even distribution but withuneventissue sensitivity, or
an uneven distribution with uneven tissue sensitivity. A better understanding of brain lithium
distribution may serve to support observations of regional specicity. The following section
aims to introduce what is known about lithium distribution within the brain.
1.3.1 Histological studies
Preclinical studies
The study of lithium distribution within the brain has until relatively recently only been
investigated in animals. Earlyex vivostudies using rats found that lithium was taken up by
different organs in unequal amounts (Schou and Mogens, 1958) and that lithium is retained in
bone following treatment cessation (Birch and Jenner, 1973). This led to a series of attempts
to characterise lithium distribution within the brain using lithium-fed rats. Almost all of these
studies reported lithium distribution to be “non-uniform” across the brain (Ebadi et al., 1974;
Ebara and Smith, 1979; Edelfors, 1975; Hanak et al., 2015; Mukherjee et al., 1976; Nelson
et al., 1976; Rios and Guzmanmendez, 1990; Smith and Amdisen, 1981; Thellier et al., 1980)
with the exception of (Bond et al., 1975). While no consensus has been reached regarding
which areas are thought to exhibit peak lithium concentrations certain patterns can be seen
across these animal studies. For example, the hypothalamus and basal ganglia have been
consistently found to contain greater lithium concentrations than the medulla and cerebellum
(Ebadi et al., 1974; Edelfors, 1975; Mukherjee et al., 1976; Nelson et al., 1976; Rios and
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Guzmanmendez, 1990), whilst another emergent trend appears to show increasing levels of
lithium from hindbrain to forebrain (Ebara and Smith, 1979; Hanak et al., 2015).
Clinical studies
The rst attempts to characterise lithium distribution in the human brain were performed
using post-mortem tissue derived from patients with bipolar disorder (Francis and Traill,
1970; Spirtes, 1976). However, these studies reached different conclusions and interpretation
was limited by low sample sizes (N = 2 and N = 1, respectively). Since the publication of
these post-mortem studies, researchers did not begin to investigate lithium within the human
brain until over a decade later (Renshaw and Wicklund, 1988). This gap was largely due to
the inability to detect lithiumin vivo. Currently, the only non-invasive means of doing so
involves the use of magnetic resonance techniques.
1.3.2 7Lithium Magnetic Resonance Spectroscopy
Quantication of lithium in the brainin vivo, whilst challenging, can be performed using
a technique called7Lithium Magnetic Resonance Spectroscopy (7Li-MRS). MRS enables
the non-invasive detection of various nuclei and compounds based upon their magnetic
resonance properties by exploiting the fact that different nuclei possess different spins. This
causes different chemical species to absorb radiofrequency energy at different frequencies
depending upon their chemical structure and local environment. During MRS, broad wave
radiofrequency energy is delivered to the target which is absorbed in different amounts
depending upon the types and concentrations of compounds present. This energy is then
emitted and detected by a receiver in the form of signal termed `free induction decay'.
Following Fourier transformation of this signal a spectrum of different peaks is obtained
whereby the position (termed chemical shift) and size of each peak corresponds to a particular
chemical species and its relative concentration, respectively (Jackson, 1992).
The identication of different compounds and their relative concentrations based upon MRS
spectra relies upon prior knowledge of expected chemical shifts and proles of peaks. This
technique is most commonly used to detect protons (1H-MRS) as protons are present in
most biologically active compounds. However, the same principles may be applied to detect
7Lithium during7Li-MRS. Developments in the eld of7Li-MRS have enabled the detection
of lithium in vivo which, when compared to a reference sample of known concentration, can
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be used to estimate lithium concentration within the brain. The rstin vivo detection of
lithium using7Li-MRS was achieved by Renshaw and Wicklund (Renshaw and Wicklund,
1988). This study acted as proof of principle study showing that it was possible to quantify
lithium in the human brain non-invasively.
Relationship between blood and brain lithium
Since the development of the ability to quantify lithiumin vivo, the relationship between
serum and brain lithium concentration has been investigated using7L -MRS in both preclin-
ical and clinical studies. Whilst preclinical studies have been fairly consistent in nding
a positive correlation between serum and brain lithium (Komoroski, 2005), results from
human studies have been more variable. For example, although there are a number of studies
that have found positive correlations between serum and brain lithium concentration (Kato
et al., 1994; Lee et al., 2012; Machado-Vieira et al., 2016; Moore et al., 2002), there are a
few studies that report weak or no correlation (Riedl et al., 1997; Sachs et al., 1995; Soares
et al., 2001). The study by Sachset al, however, found a positive relationship when all
serum concentrations (including those which fell outside of the therapeutic range) were
incorporated into the analysis. An attempt to examine this relationship over 48 hours (Plenge
et al., 1994) found that brain lithium concentration varied in accordance with serum levels
over this period, supporting the existence of a positive relationship between serum and brain
lithium concentration in humans.
In addition to investigating the relationship between serum and brain lithium, other lines of
research suggest that the ratio of concentration between lithium in plasma and red blood cells
may be a more pertinent clinical marker when monitoring lithium therapy. Lithium passes red
blood cell membranes through passive diffusion and via Li+ /Na+ counter-transport (Pandey
et al., 1978) and there is some evidence to suggest that higher concentrations of lithium in red
blood cells relative to plasma contributes towards therapeutic response and toxicity (Elizur
et al., 1982; Frazer et al., 1978). However, such ndings are limited and at present there
is insufcient evidence to warrant the use of the red blood cell / plasma lithium ratio as a
more effective clinical marker than the use of serum concentration alone (El Balkhi et al.,
2009).
Whilst a failure to nd a consistent relationship between serum and brain lithium concen-
tration in human7Li-MRS studies may be explained by an individual variability in the
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propensity for lithium to cross the blood-brain barrier, an alternative possibility may be
that lithium does not exhibit a uniform concentration throughout the brain. Studies which
have been performed using7Li-MRS are methodologically restricted to quantifying lithium
concentration within certain predened areas of the brain due to the low spatial resolution
and long acquisition times required. As a result, depending upon the study in question the
region of the brain examined may differ. If lithium distribution throughout brain tissue is
non-uniform, then studies which set their region of interest spanning different regions are
expected to nd inconsistent results.
1.3.3 7Lithium Magnetic Resonance Imaging
Whilst 7Li-MRS enables the detection of brain lithiumin vivo, this technique faces a number
of limitations such as its limited spatial resolution and long acquisition times. Although
advances are leading to faster acquisition times, the time taken to post-process spectroscopic
data means that7Li-MRS is still not routinely used in the clinic. The need for faster, higher
resolution detection of brain lithium has led to advances in7L -MRS such as7Li-MRSI (Lee
et al., 2012), however, such techniques still require long acquisition times (46 minutes) and
numerous post-processing steps.
7Lithium exhibits a spectral singletin vivo; a property which gives rise to the potential to
apply conventional MRI approaches when imaging lithium. However, lithium's low tissue
concentration and long T1 time (Smith et al., 2011) means that standard acquisition protocols
yield low signal to noise ratios. An acquisition protocol termed “balanced steady state free
precession” (b-SSFP), however, is well positioned to detect species with such properties. In
line with this, a novel acquisition technique (7Li-MRI) has recently been developed which
enables the detection of lithiumin vivo in 8 minutes (Smith et al., 2018).
The development of7Li-MRI accompanied by its rapid acquisition speed and limited number
of required post-processing steps makes this approach a signicant step forwards in terms of
its practical applications for clinical research. The rst application of this technique (Smith
et al., 2018) has revealed that lithium exhibits a heterogeneous distribution across the brains
of patients with bipolar disorder receiving long term lithium treatment (Figure 1.1).
Despite identifying heterogeneity in lithium distribution, this initial study using7Li-MRI was
carried out in a small number of patients and hence further investigation into the distribution of
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Fig. 1.17Li-MRI in eight subjects shown at the level of the head of the caudate nucleus
(upper row), with corresponding1H-MRI axial slices (middle row). The combined images
(lower row) show7Li-MRI (in cyan) overlaid on1H-MRI images. The distribution of lithium
in the brain is heterogeneous in all subjects, and varies between subjects. Image taken from
(Smith et al., 2018)
lithium is warranted. Averaged data across the subjects included in this study indicated higher
lithium signal intensity in white matter compared with grey matter, and high signal intensity
within the brain stem and corpus callosum, with notably low signal in the orbitofrontal cortex.
However, a number of variables that were not controlled for during this study such as age,
sex, comorbidities, concomitant medication and duration of treatment could all give rise
to heterogeneity in lithium distribution. Moreover, whilst this technique demonstrated the
ability to map whole-brain lithium, it only provided a snapshot of lithium distribution and
did not explore the possible variability in distribution over time. In order to examine both
the reliability of this technique and the stability of lithium distribution over time, Chapter
3 describes an original research study (Lithium Magnetic Resonance Imaging in Controls
(LiMRIC)) whereby this point is addressed through the administration of therapeutic doses
of lithium in healthy individuals.
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1.4 Summary and aims of this thesis
The effects of lithium are many-fold and whilst it is clear that lithium is effective in treating
bipolar disorder, it is not clear which of lithium's actions underpin this. In order to better
characterise lithium's effects, a multi-modal approach can be advocated. With such an
approach, the effects of lithium on the brain can be explored using a variety of metrics in
parallel and synthesised to determine whether there is consistency in the observed effects on
several putatively related parameters. Throughout this thesis original data acquired using
a variety of MRI methodologies is presented. Chapter 2 aims to provide an introduction to
structural MRI, quantitative MRI, diffusion MRI and7Li-MRI.
Current knowledge regarding the distribution of lithium in the brain is limited owing to the
longstanding lack of technical ability to map brain lithiumin vivo. The development of
7Li-MRI enables research into brain lithium distribution to be undertaken with relative ease.
However, owing to the novelty of this technique, its reliability has yet to be established. In
line with this, Chapter 3 aims to establish the reliability of7Li-MRI and temporal stability of
lithium brain distribution.
Whilst many proposals have been put forward with regards to the effects of lithium on the
brains structural properties, one which has been repeatedly replicated is the ability of lithium
treatment to promote white matter integrity, including a report which suggests that this
action of lithium might be related to treatment response (Kafantaris et al., 2017). Chapter 4
aims to explore this further through quantication of the spatial relationship between local
lithium concentration and white matter integrity using multimodal7Li-MRI and Diffusion
MRI.
Quantitative relaxometry is another technique that can be used to study changes in tissue
microstructurein vivo (see section 2.3). While there is some evidence to suggest that brain
T1 is elevated during BD and that lithium may reduce T1, this effect has only been studied in
relatively small cohorts. In order to further investigate this phenomenon, Chapter 5 reports
on regional quantication of longitudinal T1 in the brain of lithium treated and lithium-naïve
patients with bipolar disorder in comparison to healthy controls.
Chapter 2
Magnetic Resonance Image analysis
2.1 Overview
Magnetic Resonance Imaging (MRI) is an umbrella term used to describe a range of images
that can be acquired using an MRI scanner. In order to acquire such images, MRI takes
advantage of a physical phenomenon known as nuclear magnetic resonance (NMR). Despite
being underpinned by same NMR phenomenon, different acquisition protocols enable the
quantication and study of a large range of properties in biological tissue. The ndings
reported throughout this thesis were made possible by the extensive research and development
of various MRI acquisition protocols.
Whilst a comprehensive description of this NMR phenomenon is beyond the scope of
this work, the following chapter aims to introduce the various types of images that have
been acquired as part of the research carried out during the production of this thesis. This
introduction aims to provide an overview of these techniques, including a description of
their potential applications during both clinical work and research, as well as their respective
advantages and disadvantages.
2.2 T1 and T2 weighted images
The most routinely acquired MRI images are referred to as T1 weighted (T1w) and T2
weighted (T2w) images. T1w and T2w images of the human brain can be acquired rapidly
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(typically in less than ve minutes) and provide high resolution images of the brain which
confer distinct tissue contrast (Figure 2.1).
T1 and T2 weighted images are termed as such owing to the resulting observable tissue
contrast being predominately affected by either T1 (longitudinal relaxation) or T2 (trans-
verse relaxation) processes. During proton imaging, T1 relaxation is a time constant which
describes the time taken for protons to relax back to equilibrium following excitation by
an electromagnetic stimulus, while T2 describes the time taken for excited protons to “de-
phase” with one another (McRobbie et al., 2006). T1 and T2 times differ according to the
local magnetic eld strength which is determined by factors such as scanner strength and
composition of the local environment in which protons reside (Vymazal et al., 1992). MRI
acquisition protocols designed to differ in terms of their sensitivity to T1 and T2 processes
produce images in which resultant signals differ according to tissue type.
T1 and T2 weighted images can be differentiated visually according to the relative brightness
of different tissue types. In most cases T1 and T2 weighted images may be distinguished
by examining the brightness of the cerebrospinal uid (CSF), with CSF appearing dark
in T1w images and bright in T2w. However, this rule does not always apply, for example
Fluid-Attenuated Inversion Recovery (FLAIR) sequences describes a type of acquisition
protocol whereby the sequence is manipulated in order to nullify signal originating from the
CSF, a feature that is useful for highlighting periventricular abnormalities.
.
2.2.1 Uses of T1w and T2w images
Clinical use
T1 and T2 weighted images are used routinely in the clinic owing to their speed of acquisition,
high resolution and excellent tissue contrast that they confer. They can be used to identify
structural abnormalities such as tumours or lesions. For example, FLAIR images can be
used to highlight white matter hyper-intensities, a structural abnormality found to be more
prevalent in patients with bipolar disorder (Ahn et al., 2004).
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Fig. 2.1 Top: Axial slices depicting a T1 weighted image (above) and T2 weighted image
(below).
Use in research
T1w images are almost always invariably acquired alongside the acquisition of any other
additional image types during brain imaging studies owing largely to their ability to facilitate
image co-registration and tissue segmentation. A large number of linear and non-linear
image registration algorithms (Klein et al., 2009) have been specically developed to enable
the registration of T1w images of the brain to one another. The need for image registration
arises during both cross-sectional group studies and longitudinal studies. For example, in
order to track changes in the same region of the brain of a given individual over time during
multi-session studies, multiple images from the same individual must be co-registered to one
another. Intra-subject co-registration can be performed using linear registration algorithms
which permit rotation, translation, zooming and shearing of the data. In contrast, during cross-
sectional studies brain images from multiple subjects are typically aligned into a common
space. During the co-registration of multiple subjects, non-linear warping algorithms are
required. Non-linear registration permits local deformation of the data enabling images from
multiple individuals to be warped to match a common template. Such non-linear registration
involves greater distortion of the original data than linear registration and is therefore a
limitation of group analyses which are performed in standard space.
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The excellent contrast between grey and white matter that T1w images offer means that
these images are routinely used for tissue segmentation. Segmentation of brain images
enables the morphometry of individual anatomical structures to be quantied. For example,
segmentation of subcortical nuclei can be used to compare the volume of such structures
between individuals and over time. This can now be achieved with relative ease owing to the
development of software packages such as Freesurfer (https://surfer.nmr.mgh.harvard.edu/).
As a result, brain morphometry parameters such as cortical thickness, curvature, volume
and surface area are increasingly becoming commonly reported metrics in brain imaging
studies.
Freesurfer comprises a set of tools which enable the mapping of the cortical surface and
subcortical structures. The Freesurfer processing pipeline consists of two main streams,
the “surface-based” stream and “volume-based” stream. The function of the surface-based
stream is to map the boundaries between white matter, cortical grey matter, and the pial
surface (Figure 2.2A) and parcellate cortical structures, whilst the function of the volume-
based stream is to segment and label subcortical tissue structures (Figure 2.2B). Both
streams achieve this through a series of steps comprising linear registration with the with the
MNI305 atlas (Collins and Evans, 1994), image intensity normalisation via assessment of
signal variation across white matter volume (Sled et al., 1998), and intensity-based voxel
classication (Dale et al., 1999).
During cortical segmentation and parcellation, brain areas can be subdivided and labelled in
a variety of ways based upon common atlases. Voxel classication is driven by assigning
a probability based upon pre-determined labels that are encoded within a training set. By
default there are three atlases which are included within the Freesurfer processing pipeline:
the Desikan-Killiany cortical atlas (Desikan et al., 2006), Destrieux atlas (Destrieux et al.,
2010), and Desikan–Killiany–Tourville atlas (Klein and Tourville, 2012). Brain atlases
vary in terms of the number of regions that they contain which may be determined by
anatomical landmarks such as gyri and sulci, local cytoarchitecture, patterns of connectivity
or functionally specialised regions.
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Fig. 2.2 (A) Freesurfer cortical reconstruction of the pial surface and white matter boundary.
Cortical thickness is estimated by calculating the distance between the outer pial (red) and
white matter surface (yellow) . (B) Freesurfer parcellation based upon the Destrieux atlas.
2.2.2 Limitations
The major limitation associated with T1 and T2 weighted imaging arises from the fact that,
unlike quantitative imaging (see section 2.3), signals obtained are not absolute. T1 and
T2 weighted images are optimised to produce maximal grey/white matter tissue contrast,
meaning that comparison of signal intensity between sites, protocols, scanners, and time
points is challenging. There are also limitations when it comes to comparing metrics such as
cortical thickness and volume between sites and over time. For example, signal degradation
and changes in image intensity have been shown to occur over time in a phenomenon known
as scanner drift (Hansen et al., 2019). Scanner drift has been shown to inuence volumetric
measurements (Takao et al., 2011) and scanner model has also been shown to affect measure
of cortical thickness, meaning that this is something which should be controlled and corrected
for during multi-site studies (Fortin et al., 2018). When using Freesurfer to dene regions of
interest, errors may be introduced as poor image contrast can cause Freesurfer to incorrectly
classify tissue types during segmentation and parcellation. To limit this, regions of interest
can be eroded to minimise the inclusion of misclassied voxels and images should also be
inspected visually post-segmentation by trained individuals.
.
2.3 Quantitative relaxometry
Quantitative relaxometry refers to the quantication of relaxation times, such as T1 and
T2. Unlike, T1 and T2 weightedimages, which modulate acquisition sequences in order to
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optimise image contrast, signals acquired during quantitative MRI sequences (qMRI) directly
correspond to an absolute quantitative measure of time (Deoni, 2010).
The gold standard method used to quantify T1 and T2 relaxation involves the use of an acqui-
sition sequence known as “Inversion Recovery”. Inversion recovery sequences characterise
relaxation times by inverting the magnetic moment of protons using a radiofrequency (RF)
pulse and measuring the time taken for net magnetisation to fully recover. To achieve this, a
180° RF pulse is used to fully invert the net magnetisation vector (Figure 2.3A). Over time
this net magnetisation starts to recover at a rate determined by T1, during which time the net
magnetisation will pass through a null point (Figure 2.3B) . In order to characterise the T1
recovery curve, a single 90° RF pulse is applied during each recovery at varying intervals.
Through repetition of this process, the extent of recovery may be determined by recording
and plotting the net magnetisation following this RF pulse. For example, if a 90° pulse is
applied at the null point, net magnetisation becomes fully inverted once again, whereas if a
90° pulse is applied following full recovery (Figure 2.3C), net magnetisation will return to
zero.
Fig. 2.3 Following a 180° RF pulse net magnetisation is inverted (A), during recovery this
passes through a null point (B) before nally recovering to equilibrium magnetisation (C).
The time taken to fully recover is the T1 time.
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Whilst inversion recovery sequences are able to accurately quantify relaxation time, this
process takes a long time as it requires waiting for the full recovery of magnetisation. In
order to overcome this, a range of newer acquisition protocols have been developed which
enable an estimation of relaxation rates whilst minimising acquisition time.
Driven Equilibrium Single Pulse Observation of T1 (DESPOT1) is an example of such a
sequence (Deoni et al., 2005). DESPOT1 works on the basis that signal intensity in Spoiled
Gradient Recalled-Echo (SPGR) images (SISPGR) can be modelled on equations relating
the density of protons within a given voxel (proton density), longitudinal relaxation (T1),
the length of time between the application of excitation pulses (repetition time, TR), the
rotation of the net magnetisation vector (ip angle,a ) and, M0, a factor proportional to the
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Using the DESPOT1 approach, T1 parameter maps are produced via the acquisition of two
consecutive images during which the TR is held constant but the ip angle is modied. This
means that two values (x1, y1 andx2, y2 , Equation 2.2) are obtained for which the slope


















As a result, by rearranging E1 to the form shown in Equation 2.4, T1 may be calculated by
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2.3.1 Uses of qMRI
The development of rapid acquisition quantitative sequences means that qMRI is now
becoming feasible in a clinical context. One of the major advantages of qMRI over qualitative
imaging includes the ability to directly compare image signal intensity over multiple time
points and between acquisition sites. T1 and T2 relaxation serve as quantitative measures
which are sensitive to myelin, macromolecular content, iron and water content. As a result,
changes in relaxation may act as biomarkers which represent an underlying pathology. For
example, studies have used quantitative relaxometry to identify changes in iron content
during Parkinson's disease (Lee et al., 2018), visualise excess water content in malignant
gliomas (Blystad et al., 2017), map demyelination during multiple sclerosis (Manfredonia
et al., 2007), and detect hippocampal sclerosis during temporal lobe epilepsy (Jackson et al.,
1993).
2.3.2 Limitations
Whilst rapid acquisition qMRI protocols have been developed, results from studies which
use different acquisition sequences do not always match the gold standard inversion recovery
method (Tsialios et al., 2017). As such, studies which cross-compare and pool results
between sites must ensure that the same acquisition protocols and local environments are
maintained.
Another important factor to consider when applying qMRI is partial volume effects. Different
tissues vary greatly in terms of relaxation rate, and therefore if regions of interest contain
multiple tissue types results may become skewed. When using a segmentation based approach
based upon a T1w image, the means of dening a region of interest (ROI) can become circular.
This is because regions of interest are determined based upon a contrast weighted image
which, in turn, is determined by factors affecting T1 and T2. In Chapter 5 we address this
challenge by using an ROI erosion approach whereby the outer surface voxels for each
individual ROI were excluded from the analysis.
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2.4 Diffusion MRI
Diffusion weighted magnetic resonance imaging (dMRI) describes a type of acquisition
sequence designed to be sensitive to the diffusion of water molecules. The diffusion (also
termed “brownian motion”) of water describes the random displacement of water molecules as
they become agitated by thermal energy (Einstein, 1905). Owing to the fact that the diffusion
of water within the cellular space is restricted relative to extracellular water, measuring how
the diffusion of water differs across biological tissue enables inferences to be made with
regards to the brain's axonal structure.
The main principal underpinning dMRI involves the collection of multiple images whilst
exposing the target to magnetic eld gradients in differing spatial directions. When a
magnetic eld is applied to tissue, vectors of the spin polarisation begin to precess at a rate
proportional to the strength of the local magnetic eld. As a result, when a magnetic eld
is applied in the form of a spatial gradient, this causes neighbouring protons to precess at
different rates and subsequently become out of phase with one another. Diffusion MRI
exploits this phenomenon by applying two consecutive magnetic gradients of equal strength
in the opposite spatial direction to one another. This results in an effect such that if no
diffusion had occurred during this time then all protons should “re-phase” with one another.
As a result, by measuring the relative extent of “re-phasing” (which is measured in terms of
signal strength) a spatial map corresponding to the local levels of molecular diffusion can be
generated. The type of map is known as the Apparent Diffusion Coefcient (Patric Hagmann,
2006).
In addition to being able to quantify the extent of diffusion in the brain, dMRI also enables
an estimation of the relative direction or “anisotropy” of diffusion. An estimate of anisotropy
is made possible by the acquisition of images exposed to magnetic gradients in multiple
orthogonal directions. The characterisation of the diffusion prole of water can be achieved
by modelling a second order tensor (T) based on diffusion along the Cartesian axes, y and
z (Equation 2.5). In the case of fully isotropic diffusion, this tensor becomes proportional to
a 3 x 3 identity matrix.













The eigenvalues and eigenvectors associated with this tensor represent the magnitude and
direction of diffusion at a given voxel. The calculation of such eigenvalues have provided
useful metrics when it comes to the quantication of anisotropy. For example, a commonly
reported parameter during dMRI studies is Fractional Anisotropy (FA), a measure which
describes the fraction of the diffusion tensor magnitude driven by anisotropic diffusion.
Fractional anisotropy is a normalised parameter which ranges between 0-1, and in order
to estimate FA dMRI acquisition protocols must ensure to have at least six non-collinear
magnetic spatial gradients. The calculation of FA is given in Equation 2.6, wherebyl
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High levels of FA are found in white matter tracts whereby axons align in the same direction.
However, although FA has been shown to be associated with white matter integrity (Song
et al., 2008), it is a limited measure when it comes to studying areas which contain crossing
bres. In order to address this issue, advances in the modelling of diffusion have led to the
development of a parameter known as “generalised FA” (gFA) (Tuch, 2004). Generalised
FA has been shown to better characterise white matter integrity in areas containing crossing
bres by modelling diffusion using a higher order orientation distribution function. Changes
in FA and gFA within white matter have been found to occur in a large number of disorders,
including bipolar disorder (see Chapter 4).
2.4.1 Uses of dMRI
Clinical use
Although widely used throughout research, dMRI is less commonly used in the clinic.
Amongst the reasons for this current lack of translation include its relative novelty as a
2.4 Diffusion MRI 31
technique and the need for signicant image post processing in comparison to T1 and T2
weighted images. For example, parameter maps need to be generated and co-registered to
structural brain images before meaningful anatomical data can be extracted (Figure 2.4 A
and B). One of the clinical uses of dMRI which is in the process of being applied is during
neurosurgery (Conti Nibali et al., 2019). Owing to the ability to model structural connectivity
with high levels of detail, neurosurgeons are able to use this map as a tool when performing
surgery in order to minimise damage to major axonal tracts (Costabile et al., 2019). Diffusion
MRI is also useful clinically during the detection of damaged regions following a stroke
(Alegiani et al., 2019). During stroke, shutdown of the Na+ / K+ pump, leads to a net inux
of water into the cell causing water to become more restricted in terms of its ability to diffuse
randomly. As a result, ischaemic regions of brain tissue present as dark spots on ADC
parameter maps.
Use in research
The ability to model the direction and strength of the diffusion of water molecules enables
the characterisation of white matter microstructural properties and structural connectivity
in vivo. In addition to fractional anisotropy, there are a variety of other parameters that
may be extracted when tting a diffusion weighted tensor, including radial diffusivity (RD),
axial diffusivity (AD) and mean diffusivity (MD). Such parameters have been found to
reect different microstructural properties. For example, axonal injury is associated with a
reduction in FA and AD (Song et al., 2008), demyelination has been associated with increased
RD (Budde et al., 2007; Song et al., 2005), and increased myelination has been shown to
correspond with an increase in FA (Chang et al., 2017).
Owing to the fact that dMRI derived parameters can provide markers of microstructural
integrity, research has been undertaken to characterise how such properties differ in the
brain during health and disease. There are a number of approaches that may be used when
attempting to quantifying such differences. For example, using a ROI approach, parameters
may be compared across a series of atlas based segmentations (Figure 2.4C). In Chapter 4 this
approach is taken in order to quantify the differences in generalised FA between patients with
bipolar disorder and healthy controls across regions dened by the John Hopkins University
(JHU) white matter atlas. This ROI approach is useful as it enables ndings to be readily
cross-compared between studies. Additionally, the JHU atlas contains core regions of white
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matter which are not located in regions highly susceptible to image distortion such as the
orbitofrontal cortex (see section 2.4.2).
An alternative to the ROI based approach includes a voxelwise analysis, whereby parameters
such as FA are compared on an individual voxel basis. However, in order to do so images
from multiple subjects need to be accurately co-registered to one another. Moreover, owing
to the large number of comparisons being made during such analyses, statistical methods
are needed to account for the false positives. A popular approach to the voxelwise analysis
of dMRI data has been developed, known as “Tract Based Spatial Statistics” (Smith et al.,
2006). Tract Based Spatial Statistics addresses these issues by projecting individual subject
FA maps onto a “mean FA skeleton” which represents the central point of all tracts common
to the group. This skeleton is then subject to voxelwise cross subject statistics. This approach
minimises the number of comparisons being made whilst also aiming to maximise the
accuracy of between-subject registration.
The ability to detect the direction of diffusion using dMRI to infer axonal tracts has led to
the development of a method of analysis known as tractography. Tractography describes the
mapping of discrete bre tracts throughout the brain, enabling a characterisation of brain-
wide structural connectivity. The potential applications of this technique are far-reaching, for
example, graph theoretical methods are increasingly being used to quantify differences in the
structural connectome between patient and controls (O'Donoghue et al., 2017). However,
owing to rapid development of this eld there currently exists a large number of bre-tracking
algorithms each liable to generate different results (Jeurissen et al., 2019). As such, the
relationship between the dMRI-derived structural connectome and true anatomy warrants
further investigation.
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Fig. 2.4 (A) Raw diffusion MRI volumes are rstly corrected for image distortion and
processed to obtain meaningful parameters such as gFA. (B) Parameter maps are then be
co-registered to either the individual subject T1w image or standard space. (C) Co-registered
parameter maps may then be used to perform regional analysis of diffusion parameters.
2.4.2 Limitations
In addition to the need for signicant post-processing, diffusion weighted acquisition se-
quences are also susceptible to image distortion as dMRI falls under a type of imaging
sequence known as “Echo planar Imaging”. Echo planar imaging sequences enable the
acquisition of a single image in under 20 milliseconds (DeLaPaz, 1994); however, this comes
with the disadvantage of being extremely sensitive to movement and susceptibility artefacts.
For example, orbito-frontal regions appear distorted on dMRI images due to inhomogeneities
in the magnetic eld caused by the neighbouring air-lled cavity. Whilst this can be overcome
to some extent via the collection of eldmaps (Rohde et al., 2004), results gained from dMRI
nearing such regions should be interpreted with caution.
2.5 7Li-MRI
The recent development of7Li-MRI (Smith et al., 2018) marks a step forward in terms
of speed of acquisition and image resolution when it comes to detecting lithiumin vivo
compared with7Li-MRS (see section 1.3.2). However, despite this there are a number of
factors to consider when applying this technique.
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As with 1H-MRI, 7Li-MRI signal intensity is determined by T1 and T2 relaxation processes
in addition to lithium concentration and therefore does not represent a measure which can be
easily translated back into mmol/L. Despite this, results from phantom studies show a direct
correlation between7Li-MRI signal intensity and lithium concentration in pure samples
(Smith et al., 2018) and as such, voxels containing uniform tissue properties should exhibit
7Li-MRI signal that directly corresponds with lithium concentration.
The resolution of7Li-MRI, albeit higher than7Li-MRS, remains lower than well established
image acquisition protocols such as diffusion MRI. For example, typical dMRI protocols
acquire images at 2mm3 isotropic resolution, whereas the reconstructed voxel size for7Li-
MRI is 20mm x 20mm x 25mm. As a result, a large proportion of7Li-MRI voxels will
contain mixed tissue types making results susceptible to partial volume effects (Figure 2.5).
When processing7Li-MRI images at the current resolution care must be taken to ensure
that partial volume effects are accounted for. In Chapter 4 this is achieved using a tissue
segmentation approach whereby lithium voxels are treated separately depending upon their
individual tissue composition.
Fig. 2.5 Figure showing raw (non-interpolated)7Li-MRI image, illustrating an example of
partial volume effects. Each7Li-MRI voxel (top row) contains a mixture of tissue types
when overlaid onto the co-registered T1w image.
2.6 Discussion 35
2.6 Discussion
The methods used throughout this thesis and described within this chapter comprise only
a small proportion of available MRI techniques and new acquisition protocols continue to
be developed and optimised. Whilst the development of new techniques is undoubtedly a
good thing in that it enhances the toolkit which may be used to study the brain, an expanding
number of tools also comes with challenges in terms of how best to use them.
The ability to derive multiple parameters using the same acquisition protocol means that
despite acquiring the same image type, independent studies may choose to report differ-
ent parameters. For example, within the diffusion MRI literature, some studies choose
to report fractional anisotropy, whilst others choose to report changes in generalised frac-
tional anisotropy or mean diffusivity. As such, researchers are faced with a challenge of
cross-comparability between studies when different studies choose to report different post-
processing parameters. Additionally, the wide variety of readily available post-processing
methods poses a disincentive to replicate ndings when researchers can instead declare a
“novel” nding by simply reporting a new parameter. Factors such as this may be amongst the
reasons contributing to the current crisis in replicability (Baker, 2016). Given commonalities
in processing pipelines, novel analysis techniques could readily be presented alongside more
robustly established methods to strengthen comparison and better understand the evolution
of the ndings.
The ongoing rapid development of new techniques also means that studies can often dissemi-
nate new ndings before thoroughly validating a technique. The reliability and consistency
of techniques should be repeatedly and independently validatedin vivo before inferences can
be made. To this end, we report on the within subject scan-rescan reliability of7Li-MRI in
Chapter 3.
Finally, whilst a greater number of parameters can reveal more about biological propertiesin
vivo, in order to be able to interpret such properties there is a need for further studies to directly
relate changes in observable imaging parameters to biological changes. The biological
changes underpinning dMRI derived parameters have been relatively well characterised
during preclinical studies, with results linking increased fractional anisotropy to white matter
integrity and myelination; however, changes in T1 which are detected using quantitative MRI
remain challenging to interpret.

Chapter 3
Lithium Magnetic Resonance Imaging in
Controls (LiMRIC)
3.1 Abstract
The development of a novel non-invasive imaging technique (7Li-MRI) has enabled rapid
imaging of lithium distribution within the human brain (Smith et al., 2018). A preliminary
study using this technique has shown that lithium exhibits a non-uniform distribution across
the brain of patients with bipolar disorder undergoing long term lithium treatment. However,
the scan-rescan reliability of7Li-MRI has yet to be investigated; it is also not known whether
this pattern of distribution remains stable over time, nor whether brain lithium is detectable
using7Li-MRI following short term administration of lithium.
The aims of the LiMRIC study were to establish the scan-rescan reliability of7Li-MRI and
determine the stability of lithium distribution over time. To do so, healthy male subjects were
administered with lithium for two weeks and scanned using7Li-MRI on three occasions
during the nal week.
The results showed that lithium exhibited a non-uniform distribution in all subjects.7Li-
MRI images exhibited high variability in terms of raw signal magnitude between scans, but
the pattern of lithium distribution was comparable. A greater degree of correlation was
seen during within-subject comparisons when compared with between-subject comparisons;
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however, moderate correlations were also observed between subjects following smoothing
(r2 > 0.6).
This study demonstrated that lithium distribution is detectable using7Li-MRI following
short term lithium administration and the pattern of lithium distribution appears to remain
stable over the course of one week, supporting the use of this technique during short term
studies. However, variability in raw signal magnitude suggests that future analyses should
be performed on an individual subject basis, or signal normalisation should be performed
prior to any comparison of signal magnitude. Studies that aim to co-register multiple images
should consider applying smoothing to account for voxel mismatch and take care to account
for partial volume effects.
3.2 Background
The recent development of a novel magnetic resonance lithium imaging technique,7Li-MRI
(Smith et al., 2018), enables researchers to image lithiumin vivo. The aforementioned study
using this technique showed that the distribution of lithium within the brain of patients with
bipolar disorder taking lithium is heterogeneous and high lithium signal intensity was found
in white matter, notably in the brain stem and corpus callosum; however, the source of the
observed heterogeneity is currently unknown. Whilst it is possible that such heterogeneity is
reective of a true biological difference in individual uptake and handling of lithium, it is
also possible that such variability is caused by poor reproducibility of this technique.
7Li-MRI has thus far only been applied to patients with a diagnosis of bipolar disorder
receiving long-term lithium treatment. This introduces a number of potential confounders
including duration of lithium use and disease severity. Moreover, this technique has not
yet been used to determine how lithium distribution varies over time. The following study
aims to address these outstanding unknowns by using this novel technique to image lithium
within the brains of healthy individuals with no prior history of lithium use. Healthy male
volunteers were administered lithium for two weeks and scanned repeatedly over the course
of the nal week. The aims of this approach were to determine whether lithium is detectable
following short term lithium administration and to establish the scan-rescan reliability of
7Li-MRI. This was addressed across multiple time scales including within the same day, over




Four healthy male volunteers (HC) were recruited to the LiMRIC study (ages 21, 24, 25 and
45). The subjects had no history of psychiatric illness and were not taking any psychotropic
medications. Subjects were screened using the Mini-International Neuropsychiatric Interview
(v7.0) by a trained clinical research assistant (Amy-Rose Hayes). Exclusion criteria were
contraindications to magnetic resonance examination, current or recent harmful drug or
alcohol use, comorbid psychiatric diagnosis, learning disability or impairment of capacity.
All subjects provided written informed consent and the study was granted a favourable
ethical opinion by a United Kingdom National Research Ethics Committee (18/SW/0033)
and sponsored by Northumberland, Tyne and Wear NHS Foundation Trust. This study was
audited in March 2019.
Lithium administration
All subjects were prescribed lithium carbonate (Priadel™ modied release once daily),
initiated without titration based upon a dose calculated using the Cockcroft-Gault method
(Chiu et al., 2007) but capped at a maximum dose of 1000mg per day to ensure safety. The
Cockcroft-Gault method requires an estimate of kidney function, measured using a blood
sample taken during participant screening. Serum lithium levels were checked on three
occasions (study days 7, 8 and 14) by standard bloodletting. Subjects were instructed to
take their lithium dose at 9pm each evening and serum lithium sampling was performed
at 9am immediately prior to scanning. The therapeutic range in clinical practice is based
upon samples taken 12 hours post-dose. Our procedure replicated this, enabling direct
comparability between serum levels and therapeutic reference ranges. This also provided
standardisation of sampling with respect to lithium clearance across subjects ensuring that
any effects relating to brain lithium uptake were comparable between subjects. Participants
attended three 9.30am scanning sessions (study days 7, 8 and 14). During each session, two
7Li-MRI and 1H-MRI T1w structural scans were acquired. An outline of the experimental
timeline is given in Figure 3.1.
40 LiMRIC
Fig. 3.1 LiMRIC experimental design. Following an initial assessment, lithium was taken
for a period of seven days before the rst scan session. Blood samples to determine serum
lithium concentration were taken on days 7, 8 and 14.7Li-MRI took place on days 7, 8 and
14. Each scanning session included two back-to-back7Li-MRI and 1H-MRI T1w structural
scans. The nal dose of lithium was taken on the evening of day 13.
3.3.2 Image acquisition
Scanner and coil systems
All MR data were acquired on a Philips 3T Achieva scanner (Philips Medical Systems, Best,
The Netherlands) with1H structural and7Li-MRI imaging performed using a double tuned1H
/ 7Li radiofrequency (RF) birdcage head coil (RAPID Biomedical, Rimpar, Germany).
T1w image acquisition
High resolution T1w: 3D T1-weighted images of brain anatomy were acquired immediately
prior to 7Li-MRI imaging. The rst T1-weighted image was acquired with a1H gradient
echo sequence using the following parameters (TR = 9.6 ms, TE = 4.6 ms, FOV = 240 x 240
x 180 mm3, acquisition matrix = 240 x 208 x 180, acquisition voxel size = 1 x 1.15 x 1 mm3,
reconstructed into a matrix size of 256 × 256 × 180, 1 average).
Low resolution T1w: The second T1w image was acquired at half the resolution of the
high resolution T1w image in thez plane. All other acquisition parameters were kept the




Prior to data acquisition, correct radiofrequency power calibration was conrmed on a per-
subject basis with a7Li ip angle calibration. Non-localised7Li spectra were acquired at six
ip angles between 30 and 180 degrees. A sinusoidal function was tted to spectral peak
amplitudes to determine discrepancy between requested and achieved ip angle. Based upon
the results of this calculation, requested ip angles were 51° for all subjects except MR03 for
whom the requested ip angle was 54°. 7Li-MRI data acquisition commenced immediately
after T1w structural image sequences.7Li-MRI was acquired using a protocol constructed
for maximal7Li signal amplitude (FOV = 480× 480× 175 mm3, 20× 19 × 7 acquisition
matrix and 24.0 x 25.3 x 25.0 mm3 voxel size, with TR = 9.4 ms, TE = 4.5 ms, receiver
bandwidth = 219 Hz/pixel, 500 averages per dynamic, 3 dynamics). Data were reconstructed
into a 32× 32 × 7 matrix with a voxel size of 15× 15 × 25 mm3. The sequence, lasting
approximately eight minutes, was conducted thrice without a notable interval and the three
scan dynamics were averaged in complex form.
Scanning protocol
Scan sessions took place on study days 7, 8 and 14. On study days 7 and 8, two7Li-MRI
scans were taken in order to investigate the effect of removal from scanner on scan-rescan
reliability. On study day 7 subjects remained in the scanner throughout the whole session.
On study day 8 subjects were removed and repositioned in the scanner following acquisition
of the rst 7Li-MRI scan. On study day 14 two scanning blocks were completed, but the
nal block was used for sequence development for a different project not presented here. An
outline of the scanning protocol is shown in Figure 3.2.
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Fig. 3.2 LiMRIC scan protocol. During each session T1w image acquisition preceded7Li-
MRI acquisition. The rst T1w acquisition was high resolution. On study day 7 subjects
remained in the scanner throughout the whole session. On study day 8 subjects were removed
and repositioned into the scanner between7Li-MRI scans.
3.3.3 Image processing and analysis
T1w and7Li-MRI images were exported in DICOM format and converted to NIFTI format
data using MRIconvert version 2.0 for Windows (Lewis Center for Neuroimaging, University
of Oregon, OR, USA).7Li-MRI data for MR02 Day 7 Scan 2 was unavailable due to
le corruption during export from the scanner. Data pre-processing and analysis were
performed using Nipype, a Python based platform that provides a uniform interface to
existing neuroimaging software and facilitates interaction between these packages within a
single workow (Gorgolewski et al., 2011).
Image resampling and co-registration
The T1w images of each subject were linearly co-registered to their respective initial T1w
image collected during the rst imaging session (study day 7) using FMRIB's Linear Image
Registration Tool (Jenkinson et al., 2012).7Li-MRI images were resampled to the resolution
of the T1w image using nearest neighbour and linear interpolation. Linearly interpolated
images were used for display purposes, whilst all analyses were performed using nearest
neighbour interpolated images. Resampled7Li-MRI images were then transformed by
applying the transformation matrix obtained from registering the structural T1w images to
the T1w image collected during study day 7.
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Image post-processing
Co-registered7Li-MRI images were masked for brain-only voxels using a binary mask
generated by applying FSL's Brain Extraction Tool to the co-registered T1w image (Smith
et al., 2002). Following masking,7Li-MRI images were smoothed using a Gaussian kernel
of full width half maximum sizes ranging from 0mm - 4mm in increments of 1mm.7Li-MRI
images were then downsampled to the original7Li-MRI resolution.
An estimation of noise per7Li-MRI image was achieved by averaging all background signal.
To do so, the FSL“outskin mask” function was used to obtain a mask encompassing all bodily
tissue. The inverse of this mask was subsequently used to sample background signal.
Quantication of cross-scan comparability
Brain voxels from co-registered downsampled7Li-MRI images were regressed against one
another in order to determine the correlation between separately acquired7Li-MRI images.
Between scan correlation was assessed within the same session (removed from scanner vs
remained in scanner) and between sessions (study days 7 vs 8 vs 14). In order to establish a
reference point, the same process was applied to corresponding T1w images.
MNI space analysis
In order to conduct a between-subject comparison, all7Li-MRI images were additionally
registered to the Montreal Neurological Institute standard space brain template (2mm resolu-
tion). This was achieved by non-linear warping of every T1w image from every subject and
session individually to this template using FMRIB's Non Linear Image Registration Tools
(Jenkinson et al., 2012). The resulting transformation matrix was then used to transform every
resampled7Li-MRI image individually. Standard space co-registered images were smoothed
and downsampled to the original7Li-MRI resolution following the same post-processing
steps as during the within-subject analysis.
The correlation between7Li-MRI brain voxels was calculated pairwise for all combinations
of images which were classied as either “within” or “between” subject. A schematic
illustrating the resulting variations of comparisons is given in Figure 3.3. Signicance
between the difference in r2 values for within versus between subject comparisons was tested
using a Wilcoxon signed rank test after conrmation that data was non-normally distributed
using the Lillefors test of normality.
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Fig. 3.3 Schematic illustrating how difference combinations of within vs. between subject
7Li-MRI comparisons were generated. Pearson's r2 values were computed for all various
combinations of7Li-MRI image comparisons and classied as either “within” or “between”
subject.
3.4 Results
3.4.1 7Li-MRI raw scans
7Li-MRI raw images for subjects MR02, MR03, MR04 and MR05 are shown in Figures
3.4, 3.5, 3.6 and 3.7, respectively. Some degree of consistency in terms of the pattern of the
lithium distribution can be seen visually both within and between subjects.
